» Articles » PMID: 34631756

Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990-2019: Results From the Global Burden of Disease Study 2019

Overview
Specialty General Medicine
Date 2021 Oct 11
PMID 34631756
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Non-Hodgkin lymphoma is a common hematologic malignancy. This article aimed to estimate the trends of non-Hodgkin lymphoma (NHL) globally from 1990 to 2019. Data on the NHL burden were explored from the Global Burden of Disease study 2019. The trends of NHL burden were estimated using age-standardized rate (ASR) and estimated annual percentage change (EAPC). The ASR of NHL incidence showed an increasing trend worldwide from 1990 to 2019, with an EAPC of.56 [95% CI: 0.45-0.66]. Meanwhile, increasing trends were observed in both sexes and in most geographic regions, particularly East Asia (EAPC = 3.57, 95% CI: 3.29-3.86). The most pronounced increasing trends were seen in Georgia (EAPC = 4.7, 95% CI: 4.20-5.21), followed by Belarus and Uzbekistan. However, death and disability-adjusted life years (DALYs) caused by NHL showed decreasing trends globally, in which the respective EAPCs were -0.09 (95% CI: -0.17 to -0.02) and -0.28 (95% CI: -0.35 to -0.22). Decreasing trends were mainly seen in high and high-middle sociodemographic index (SDI) areas. At the national level, the largest increasing trends of death and DALYs were observed in Georgia, in which the respective EAPCs were 4.54 (95% CI: 4.01-5.07) and 4.97 (95% CI: 4.42-5.52). Decreasing trends of death and DALYs caused by NHL were observed worldwide from 1990 to 2019, but NHL remains a substantial challenge globally. The findings would inform the strategies for reducing the burden of NHL.

Citing Articles

Fifteen Years of Non-Hodgkin Lymphoma in an Indonesian National Referral Hospital: Epidemiologic Trends and Diagnostic Challenges.

Harahap A, Ham M, Kurniawan A, Charles S, Wijovi F, Sukrisman L JCO Glob Oncol. 2024; 10:e2400346.

PMID: 39509674 PMC: 11583351. DOI: 10.1200/GO-24-00346.


Safety of Rituximab biosimilar (Riximyo®) following a single switch from the reference product in patients with Non-Hodgkin's lymphoma: a retrospective study.

Song N, Musa H, Soriano M, Hibbs D, Ramzan I, Ong J Ann Hematol. 2024; 103(11):4607-4612.

PMID: 39249493 PMC: 11534887. DOI: 10.1007/s00277-024-05981-9.


Etiology of non-Hodgkin lymphoma: A review from epidemiologic studies.

Luo J, Craver A, Bahl K, Stepniak L, Moore K, King J J Natl Cancer Cent. 2024; 2(4):226-234.

PMID: 39036553 PMC: 11256700. DOI: 10.1016/j.jncc.2022.08.003.


Global spatiotemporal distributions of lymphoma from 1990 to 2019: A Joinpoint regression analysis based on the global burden of disease study 2019, and projections until 2044.

Liu J Dialogues Health. 2024; 4:100182.

PMID: 38846580 PMC: 11153881. DOI: 10.1016/j.dialog.2024.100182.


High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma.

Daneels W, Van Parys A, Huyghe L, Rogge E, De Rouck S, Christiaen R Exp Hematol Oncol. 2024; 13(1):59.

PMID: 38831452 PMC: 11145843. DOI: 10.1186/s40164-024-00524-4.


References
1.
Gascoyne R, Aoun P, Wu D, Chhanabhai M, Skinnider B, Greiner T . Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999; 93(11):3913-21. View

2.
Ortega-Garcia J, Lopez-Hernandez F, Carceles-Alvarez A, Fuster-Soler J, Sotomayor D, Ramis R . Childhood cancer in small geographical areas and proximity to air-polluting industries. Environ Res. 2017; 156:63-73. PMC: 5685507. DOI: 10.1016/j.envres.2017.03.009. View

3.
Ou Z, Yu D, Liang Y, He W, Li Y, Zhang M . Analysis of the Global Burden of Disease study highlights the trends in death and disability-adjusted life years of leukemia from 1990 to 2017. Cancer Commun (Lond). 2020; 40(11):598-610. PMC: 7668511. DOI: 10.1002/cac2.12094. View

4.
Nair R, Arora N, Mallath M . Epidemiology of Non-Hodgkin's Lymphoma in India. Oncology. 2016; 91 Suppl 1:18-25. DOI: 10.1159/000447577. View

5.
. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 385(9963):117-71. PMC: 4340604. DOI: 10.1016/S0140-6736(14)61682-2. View